Linical Co

Linical Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Linical Co (2183.T) as of Nov 11, 2026 is 46.66 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -111.71 % — a change of -141.77% (higher).

FCF Conversion

46.66 %

YoY

-141.77%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Linical Co is 2026 46.66 % . FCF Conversion Rate (FCF/EBITDA) of Linical Co was 2025 -111.71 % . It decreases by -141.77% higher compared to the previous year.

The Linical Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2019
-146.74 JPY
Jan 1, 2020
219.58 JPY
Jan 1, 2021
-8.31 JPY
Jan 1, 2022
200.55 JPY
Jan 1, 2023
181.85 JPY
Jan 1, 2024
318.60 JPY
Jan 1, 2025
-111.71 JPY
Jan 1, 2026
46.66 JPY
The Linical Co FCF Conversion history
YEARFCF ConversionYoY
46.66 %-141.77%
-111.71 %-135.06%
318.60 %+75.21%
181.85 %-9.33%
200.55 %-2,512.30%
-8.31 %-103.79%
219.58 %-249.64%
-146.74 %-246.40%
100.24 %-35.90%
156.37 %+17.01%
133.64 %-13.60%
154.67 %+192.25%
52.93 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Linical Co Stock analysis

What does Linical Co do? Linical Co., Ltd. generates revenue through two distinct business segments, the CRO segment and the Pharmaceutical Sales Support segment. The CRO segment provides contract monitoring, quality management, and consulting services specifically for phase II and phase III in drug development processes. These services are delivered to pharmaceutical companies as part of pharmaceutical contract research projects. The Pharmaceutical Sales Support segment focuses on the downstream market by providing pharmaceutical sales support for medical institutions. The company operates these businesses from its headquarters in Osaka, Osaka-Fu, leveraging its workforce of 759 full-time employees to deliver these specialized services. Linical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linical Co stock

FCF Conversion Rate (FCF/EBITDA) of Linical Co is 46.66 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Linical Co changed from -111.71 % to 46.66 %, representing a -141.77% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Linical Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Linical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Linical Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Linical Co